Scientists have identified a synthetic mini-antibody from Llama

Scientists have identified a synthetic mini-antibody from Llama

Unusually small antibodies present in the blood of llamas are the source behind one of the new weapons against Covid-19. Scientists have identified a synthetic mini-antibody that is capable of blocking SARS-CoV-2, the virus that triggers Covid-19, from binding to human cells and invading tissues.

Scientists have identified a synthetic mini-antibody from Llama

The synthesis of mini-antibodies consists of a special form of small nanobodies anti microorganism called Camelid’s blood, an animal family that comprises camels, llamas, alpacas and vicuñas.

Nanobody content has been detected in other mammals and has proven a promising agent against viruses due to their size and versatility, approximately one-tenth of the size of the traditional antibody Interestingly, earlier this year research has also shown that flame nanobodies can attach to SARS-CoV-2, which prevents the virus from entering a cell.

Luckily, scientific researchers do not often need to directly drain these nanobodies from the blood of the blaze. This technology allows researchers to reasonably easily pick synthetic nanobodies, which are called bodies. A recent analysis, which was published in Nature Communications, found a new library of bodies by researchers from the European Molecular Biology Laboratory in Hamburg, Germany, who attempted to classify those targeting the SARS-CoV-2 spike protein.

A notable promise was found for one of the bodies — named Sb23. They studied how Sb23 interacts with the receptor-binding domains of viruses with a tool to detail nano-binding objects called X-ray scattering in small angles. They have tested how Sb23 is performing with a virus modified to produce a spike protein SARS-CoV-2 that is the key that the virus uses for entry into a host cell. Essentially, the modified virus was successfully disabled in vitro by Sb23.

Of course, it is a very different job to deactivate a modified virus in a petri dish to produce a SARS-CoV-2 infection in the human body. However, thanks to their synthetic nanobody library, the investigators have accomplished this study in just under three weeks. They believe that this new study shows that important steps in nanobody research can now be made in a relatively short time, helping to pave the way for the creation of more nanobody-based medicines against diseases, particularly Covid-19.

“This approach is an attempt to reduce and plan for future pandemics the overwhelming effect SARS-CoV-2 has on health systems. Those who are researchers conclude in their papers that the R&D group should act promptly to produce effective medication.

“Here we demonstrate that it is possible to select highly specific binders with neutralizing activity against SARS-CoV-2 from a synthetic nanobody library in a timeframe of only 2–3 weeks. The traditional generation of nanobodies requires at least 6 weeks for the Llama immunization and a total of 3-4 months for the entire selection approach.”

Scientists have identified a synthetic mini-antibody from Llama

Rajat Singh
Rajat Singh is the chief Author at Bioinformatics India, he has been writing for the past 3 years and has a special interest in SEO, Technology, Health, Life Sciences and gaming.

Get in Touch

Related Articles

Get in Touch


Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest Posts